CoChat

Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer’s Disease

Open access
Guzior, Natalia, Wi.eckowska, Anna, Panek, Dawid, Malawska, Barbara · 2014 · Current Medicinal Chemistry

The DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index.

Abstract

Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder. The available therapy is limited to the symptomatic treatment and its efficacy remains unsatisfactory. In view of the prevalence and expected increase in the incidence of AD, the development of an effective therapy is crucial for public health. Due to the multifactorial aetiology of this disease, the multi-target-directed ligand (MTDL) approach is a promising method in search for new drugs for AD. This review updates information on the development of multifunctional potential anti-AD agents published within the last three years. The majority of the recently reported structures are acetylcholinesterase inhibitors, often endowed with some additional properties. These properties enrich the pharmacological profile of the compounds giving hope for not only symptomatic but also causal treatment of the disease. Among these advantageous properties, the most often reported are an amyloid-β antiaggregation activity, inhibition of β-secretase and monoamine oxidase, an antioxidant and metal chelating activity, NOreleasing ability and interaction with cannabinoid, NMDA or histamine H3 receptors. The majority of novel molecules possess heterodimeric structures, able to interact with multiple targets by combining different pharmacophores, original or derived from natural products or existing therapeutics (tacrine, donepezil, galantamine, memantine). Among the described compounds, several seem to be promising drug candidates, while others may serve as a valuable inspiration in the search for new effective therapies for AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/0929867321666141106122628

Cites

240 of 240 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig.(1) Drugs approved for the treatment of AD.
Fig.(1) Drugs approved for the treatment of AD.CC BY-NC · PubMed Central
Fig.(2) Structures of selected multifunctional ligands, potential anti-Alzheimer's drugs.
Fig.(2) Structures of selected multifunctional ligands, potential anti-Alzheimer's drugs.CC BY-NC · PubMed Central
Fig.(3) Tacrine heterodimers as cholinesterase and Aβ aggregation inhibitors.
Fig.(3) Tacrine heterodimers as cholinesterase and Aβ aggregation inhibitors.CC BY-NC · PubMed Central
Fig.(4) Donepezil-related derivatives with Aβ anti-aggregation activity.
Fig.(4) Donepezil-related derivatives with Aβ anti-aggregation activity.CC BY-NC · PubMed Central
Fig.(5) Benzotriazinones and triazafluoranthenones with AChE/BuChE inhibitory activity and Aβ anti-aggregation activity.
Fig.(5) Benzotriazinones and triazafluoranthenones with AChE/BuChE inhibitory activity and Aβ anti-aggregation activity.CC BY-NC · PubMed Central
Fig.(6) Diarylimidazole derivatives - selective BuChE and Aβ aggregation inhibitors.
Fig.(6) Diarylimidazole derivatives - selective BuChE and Aβ aggregation inhibitors.CC BY-NC · PubMed Central
Fig.(7) Isaindigotone derivative as dual cholinesterase and Aβ aggregation inhibitor.
Fig.(7) Isaindigotone derivative as dual cholinesterase and Aβ aggregation inhibitor.CC BY-NC · PubMed Central
Fig.(8) Structure of multifunctional derivative of isoquinoline - chelerythrine - an inhibitor of hAChE, hBuChE and Aβ aggregation.
Fig.(8) Structure of multifunctional derivative of isoquinoline - chelerythrine - an inhibitor of hAChE, hBuChE and Aβ aggregation.CC BY-NC · PubMed Central
Fig.(9) Multifunctional coumarin and chalcone derivatives with AChE/BuChE and Aβ aggregation inhibitory activity.
Fig.(9) Multifunctional coumarin and chalcone derivatives with AChE/BuChE and Aβ aggregation inhibitory activity.CC BY-NC · PubMed Central
Fig.(10) Tacrine-4-oxo-4H-chromene hybrids as AChE, BuChE and BACE1 inhibitors.
Fig.(10) Tacrine-4-oxo-4H-chromene hybrids as AChE, BuChE and BACE1 inhibitors.CC BY-NC · PubMed Central
Fig.(11) Huprine based hybrids - hAChE, hBuChE, BACE1 and Aβ aggregation inhibitors.
Fig.(11) Huprine based hybrids - hAChE, hBuChE, BACE1 and Aβ aggregation inhibitors.CC BY-NC · PubMed Central
Fig.(12) Multifunctional pyrimidine derivatives with AChE/BuChE, BACE1 and Aβ inhibitory activity.
Fig.(12) Multifunctional pyrimidine derivatives with AChE/BuChE, BACE1 and Aβ inhibitory activity.CC BY-NC · PubMed Central
Fig.(13) Benzamide derivatives as AChE/BuChE, BACE1 inhibitors.
Fig.(13) Benzamide derivatives as AChE/BuChE, BACE1 inhibitors.CC BY-NC · PubMed Central
Fig.(14) Tryptoline and tryptamine triazole derivatives - BACE1 and Aβ aggregation inhibitors with antioxidant and metal chelating properties
Fig.(14) Tryptoline and tryptamine triazole derivatives - BACE1 and Aβ aggregation inhibitors with antioxidant and metal chelating propertiesCC BY-NC · PubMed Central
Fig.(15) Benzylpiperidine derivatives as MAO inhibitors with anti-cholinesterase activity.
Fig.(15) Benzylpiperidine derivatives as MAO inhibitors with anti-cholinesterase activity.CC BY-NC · PubMed Central
Fig.(16) Tacrine derivatives with MAO and cholinesterase inhibitory activity.
Fig.(16) Tacrine derivatives with MAO and cholinesterase inhibitory activity.CC BY-NC · PubMed Central
Fig.(17) Pyrazoline derivatives with MAO and AChE inhibitory activity.
Fig.(17) Pyrazoline derivatives with MAO and AChE inhibitory activity.CC BY-NC · PubMed Central
Fig.(17) Multifunctional berberine derivatives with antioxidant activity.
Fig.(17) Multifunctional berberine derivatives with antioxidant activity.CC BY-NC · PubMed Central
Fig.(19) Tacrine derivatives with the antioxidant properties.
Fig.(19) Tacrine derivatives with the antioxidant properties.CC BY-NC · PubMed Central
Fig.(20) Tacrine hybrids - cholinesterase and Aβ aggregation inhibitors with antioxidant properties.
Fig.(20) Tacrine hybrids - cholinesterase and Aβ aggregation inhibitors with antioxidant properties.CC BY-NC · PubMed Central
Fig.(21) Donepezil-ebselen hybrid compounds - cholinesterase inhibitors with the antioxidant properties.
Fig.(21) Donepezil-ebselen hybrid compounds - cholinesterase inhibitors with the antioxidant properties.CC BY-NC · PubMed Central
Fig.(22) Carbamate derivatives of indoline with antioxidant properties and anti-cholinesterase activity.
Fig.(22) Carbamate derivatives of indoline with antioxidant properties and anti-cholinesterase activity.CC BY-NC · PubMed Central
Fig.(23) Lipoic acid derivatives as antioxidants and cholinesterase inhibitors.
Fig.(23) Lipoic acid derivatives as antioxidants and cholinesterase inhibitors.CC BY-NC · PubMed Central
Fig.(24) Curcumin and its dimethylaminomethyl-substituted derivatives as antioxidants
Fig.(24) Curcumin and its dimethylaminomethyl-substituted derivatives as antioxidantsCC BY-NC · PubMed Central
Fig.(25) Flavonoid derivatives as cholinesterase inhibitors with Aβ anti-aggregating and metal chelating properties.
Fig.(25) Flavonoid derivatives as cholinesterase inhibitors with Aβ anti-aggregating and metal chelating properties.CC BY-NC · PubMed Central
Fig.(26) Coumarin and rhein derivatives as cholinesterase inhibitors with metal chelating properties.
Fig.(26) Coumarin and rhein derivatives as cholinesterase inhibitors with metal chelating properties.CC BY-NC · PubMed Central
Fig.(27) Indanone derivatives as cholinesterase and monoamine oxidase inhibitors with metal chelating properties.
Fig.(27) Indanone derivatives as cholinesterase and monoamine oxidase inhibitors with metal chelating properties.CC BY-NC · PubMed Central
Fig.(28) Rutaecarpine derivative as a multifunctional metal chelator.
Fig.(28) Rutaecarpine derivative as a multifunctional metal chelator.CC BY-NC · PubMed Central
Fig.(29) Resveratrol derivatives as metal-chelating agents with additional biological properties.
Fig.(29) Resveratrol derivatives as metal-chelating agents with additional biological properties.CC BY-NC · PubMed Central
Fig.(30) Tacrine-ferulic acid-NO-donor trihybrid and its precursors.
Fig.(30) Tacrine-ferulic acid-NO-donor trihybrid and its precursors.CC BY-NC · PubMed Central
Fig.(31) Tacrine-flurbiprofen hybrid compound and its NO-releasing analogue.
Fig.(31) Tacrine-flurbiprofen hybrid compound and its NO-releasing analogue.CC BY-NC · PubMed Central
Fig.(32) Galantamine and its simplified analogue with NO-releasing nitrate group.
Fig.(32) Galantamine and its simplified analogue with NO-releasing nitrate group.CC BY-NC · PubMed Central
Fig.(33) 4-Phenyl-2-aminothiazole-tacrine hybrids - cholinesterase and Aβ aggregation inhibitors with Ca2+ overload blocking activity.
Fig.(33) 4-Phenyl-2-aminothiazole-tacrine hybrids - cholinesterase and Aβ aggregation inhibitors with Ca2+ overload blocking activity.CC BY-NC · PubMed Central
Fig.(34) N-acylamiophenothiazine derivative with the neuroprotective activity.
Fig.(34) N-acylamiophenothiazine derivative with the neuroprotective activity.CC BY-NC · PubMed Central
Fig.(35) Cystamine-tacrine dimer.
Fig.(35) Cystamine-tacrine dimer.CC BY-NC · PubMed Central
Fig.(36) Memagal - a chimera derivative of galantamine and memantine.
Fig.(36) Memagal - a chimera derivative of galantamine and memantine.CC BY-NC · PubMed Central
Fig.(37) Latrepirdine-based bivalent ligand with anti-cholinesterase, Aβ anti-aggregation activity and neuroprotective effect.
Fig.(37) Latrepirdine-based bivalent ligand with anti-cholinesterase, Aβ anti-aggregation activity and neuroprotective effect.CC BY-NC · PubMed Central
Fig.(38) LY320135 - CB1 receptor antagonist and MTDLs against AD, targeting AChE, BuChE, amyloid-β formation and cannabinoid receptors.
Fig.(38) LY320135 - CB1 receptor antagonist and MTDLs against AD, targeting AChE, BuChE, amyloid-β formation and cannabinoid receptors.CC BY-NC · PubMed Central
Fig.(39) Indole-based CB2 receptor agonist JWH-015 and indazole-based compounds CB2 receptor agonists with BuChE inhibitory activity and antioxidant properties.
Fig.(39) Indole-based CB2 receptor agonist JWH-015 and indazole-based compounds CB2 receptor agonists with BuChE inhibitory activity and antioxidant properties.CC BY-NC · PubMed Central
Fig.(40) Dual-acting diether derivatives of homopiperidine with histamine H3 receptor antagonistic and anticholinesterase activity.
Fig.(40) Dual-acting diether derivatives of homopiperidine with histamine H3 receptor antagonistic and anticholinesterase activity.CC BY-NC · PubMed Central
Fig.(41) Tri- and tetracyclic derivatives acting as dual AChE inhibitors and hH3 receptor antagonists
Fig.(41) Tri- and tetracyclic derivatives acting as dual AChE inhibitors and hH3 receptor antagonistsCC BY-NC · PubMed Central
Fig.(42) An isoliquiritigenin derivative with activity against 5-LO and Aβ aggregation.
Fig.(42) An isoliquiritigenin derivative with activity against 5-LO and Aβ aggregation.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 240 references

Cited by

See all 364

Metadata

Authors
Guzior, N., Wi.eckowska, A., Panek, D., & Malawska, B.
Affiliations
Jagiellonian University (PL)
Corresponding author
Malawska, Barbara
Venue
Current Medicinal Chemistry
Published
2014-12-19
Volume
22
Issue
3
Pages
373-404
ISSN
0929-8673 (ISSN-L)
OpenAlex
W2160250661
Cited by
323
References
239
Citations by year
2026: 10 · 2025: 10 · 2024: 20 · 2023: 24 · 2022: 28 · 2021: 29 · 2020: 26 · 2019: 40 · 2018: 46 · 2017: 41 · 2016: 36 · 2015: 12
FWCI
4.00
Type
journal article
Language
en
Open access
Locations
  • Current Medicinal Chemistry (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion)
  • Jagiellonian University Repository (Jagiellonian University) (submittedVersion, other-oa)
  • Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
  • Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
Funders
Narodowym Centrum Nauki
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, multi-target-directed ligands, acetylcholinesterase inhibitors, beta-secretase inhibition, monoamine oxidase inhibition, antioxidant activity, metal chelation, nitric oxide release, cannabinoid receptors, NMDA receptor, histamine H3 receptor, tacrine, donepezil, galantamine, memantine, drug candidates
MeSH terms
Alzheimer Disease, Animals, Enzyme Inhibitors, Humans, Amyloid beta-Peptides, Neuroprotective Agents, Drug Discovery, Protein Aggregates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer’s Disease. https://app.cochat.ai/papers/10.2174/0929867321666141106122628
The paper
Guzior, N., Wi.eckowska, A., Panek, D., & Malawska, B. (2014). Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer’s Disease. Current Medicinal Chemistry. https://doi.org/10.2174/0929867321666141106122628

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.